D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. Issue 2 (March 2014)

• Record Type: Journal Article
• Authors: Kimura, Shun-ichi; Wada, Hidenori; Ishihara, Yuko; Kawamura, Koji; Sakamoto, Kana; Yamasaki, Ryoko; Ashizawa, Masahiro; Machishima, Tomohito; Sato, Miki; Terasako, Kiriko; Nakasone, Hideki; Kikuchi, Misato; Okuda, Shinya; Kako, Shinichi; Kanda, Junya; Yamazaki, Rie; Tanihara, Aki; Nishida, Junji; Kanda, Yoshinobu
• Is Part Of: Hematology. Volume 19:Issue 2(2014)
• Page Start: 107
• Page End: 112
• Publication Date: 2014-03
• Subjects: Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1179/1607845413Y.0000000103
• Languages: English
• ISSNs: 1024-5332

Abstract

<abstract> <title> <x content-type="archive" xml:space="preserve">Abstract</x> </title> <p>The D-index is calculated as the area over the neutrophil curve during neutropenia. We investigated the impact of the D-index on pulmonary infection in 33 acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine. There was no difference in the D-index between chemotherapies with and without pulmonary infection. The cumulative D-index (c-D-index) until the development of infection exceeded 4000 in four of five patients with pulmonary infection. Although there was no difference in the total D-index throughout the overall consolidation chemotherapy, the total D-index from induction to consolidation and the D-index at induction chemotherapy were higher in patients with pulmonary infection during consolidation than in those without it (<italic>P</italic> = 0.014 and 0.019, respectively). Our results showed that the cumulative effect of neutropenia might determine the risk of pulmonary infection in consolidation chemotherapy. We are planning a clinical trial of c-D-index-guided preemptive antifungal therapy.</p> </abstract>